David A. Hyman, MD, JD, on Inclusive Shared Savings

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Welcome and Introduction to Vi3C

Amit Sanyal, MD: A Clinician’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Feb

Today In Oncology

David A. Hyman, MD, JD, on Inclusive Shared Savings

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Welcome and Introduction to Vi3C

Amit Sanyal, MD: A Clinician’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

A New Risk Model for Esophagectomy Draws on the STS National Database

Olaparib in Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA

Ultra–Low-Dose Immunotherapy in Relapsed or Refractory Solid Tumors

ASCO and Conexiant Launch ASCO AI in Oncology

Self-Acupressure May Ease Fatigue in Ovarian Cancer Survivors